Regeneron Pharmaceuticals, Inc. (LON:0R2M)

Market Cap	59.29B
Revenue (ttm)	11.34B
Net Income (ttm)	3.52B
Shares Out	n/a
EPS (ttm)	30.62
PE Ratio	16.82
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	Feb 20, 2025

Volume	32
Average Volume	1,998
Open	698.56
Previous Close	696.26
Day's Range	692.47 - 701.48
52-Week Range	677.13 - 998.57
Beta	n/a
RSI	52.53
Earnings Date	Feb 3, 2025

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous sq...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1988
• Employees: 15,106
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0R2M

Financial Performance

In 2024, Regeneron Pharmaceuticals's revenue was $14.20 billion, an increase of 8.27% compared to the previous year's $13.12 billion. Earnings were $4.41 billion, an increase of 11.61%.

Financial numbers in USD